Ogivri® approved by Health Canada for treatment of breast cancer and metastatic stomach cancer

May 22, 2019

Health Canada approves Ogivri® for the treatment of HER2-positive breast cancer and HER2-positive metastatic stomach cancer. The product is the first TmAb biosimilar to be approved in Canada and is expected to be launched in the current quarter.

Print Page Mail Article